Bonjour ,
Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.
% complété
%
1 Ce profil est validé par 1 label.
Company
Bio Optical Detection
25
EQ SCORE L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Bio Optical Detection has developed a fully functional allergy diagnostic device (TRL 6), presented at Europe’s largest medical industry trade fair. Currently, we are working to commercialize the device, with the market launch planned for 2022.
Mejorada del Campo, Madrid, Spain
Send a message
Anglais
Bio Optical Detection
Anglais
Bio Optical Detection S.L. (biod) was initially conceived by scientists from the Optics, Photonics and Bio-Photonics research group based at the Centre of Biomedical Technology, Technical University of Madrid. After its founding in 2010, the company focused primarily on R&D activities in collaboration with public and private institutions (e.g., the then Spanish Ministry of Economics and Competitiveness, which funded ATAPoC, a point-of-care allergy diagnostic project (Grant...
Bio Optical Detection S.L. (biod) was initially conceived by scientists from the Optics, Photonics and Bio-Photonics research group based at the Centre of Biomedical Technology, Technical University of Madrid. After its founding in 2010, the company focused primarily on R&D activities in collaboration with public and private institutions (e.g., the then Spanish Ministry of Economics and Competitiveness, which funded ATAPoC, a point-of-care allergy diagnostic project (Grant RTC-2015-3273-1), and Horus Pharma, which funded development of our first technology demonstrator through an engineering contract).
In 2017, a new shareholder joined biod, providing €130,000 of seed money, and the company pivoted towards bringing its own solution to the market. Since autumn 2017, it has been the lead commercial partner within the project AllerScreening (a research and innovation action supported by the EU Horizon 2020 programme, Grant 768641). To further support its growth plans, biod has begun offering screening services for pharmaceutical companies, generating its first revenues not derived from R&D projects.
In November 2019, biod presented a fully functional allergy diagnostic device (TRL 6) at MEDICA 2019 in Düsseldorf, Europe’s largest medical industry trade fair. Currently, we are working to commercialise the device, with the market launch planned for 2022.
Team member(s)
Your request has been sent
Join this organization
Your request has been sent
Our network
Your request has been sent
Join this network
Your message has been sent
Certifications
The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.
This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.
456 Entities
Communities
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding
for selected DEEP TECH companies.
2675 Members
Our history
Start in Founding
-
Founding
After winning 2nd prize of innovation challenge at Technical University Madrid.
-
First major projects grant
Under the EU-FP7 umbrella. The project was called "EnviGuard" and it had a focus on aquaculture.
-
MVP
First private project. Developed with Bioftalmik and Horus Pharma with a focus on ophtalmology.
-
First patent
Exclusive patent granted for technology initially developed at UPM.
-
EU H2020 project
Commercial lead partner within EU H2020 project called AllerScreening, focused on food allergies.
to be continued ...